Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Environmental Health: Advancing Emancipatory Policies for the Common Good.

ANS. Advances in nursing science·2017

Same author

What do nurse practitioners do? Analysis of a skills survey of nurse practitioners.

Journal of the American Association of Nurse Practitioners·2013

Same author

Greening in healthcare.

Nursing management·2010

Same author

Drug approvals: '08 in review. Nebivolol (Bystolic).

The Nurse practitioner·2009

Same author

Drug approvals: '08 in review. Certolizumab pegol (Cimzia).

The Nurse practitioner·2009

Same author

Drug approvals: '08 in review. Desvenlafaxine (Pristiq).

The Nurse practitioner·2009

Search research articles

Related Experiment Video

Updated: Jul 25, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Drug approval highlights for 2003.

Gary Laustsen¹, Lynn Wimett

¹Regis University, Denver, Colorado, USA.

The Nurse Practitioner

|February 12, 2004

Summary

The FDA approved new drugs for common conditions like incontinence, herpes, and erectile dysfunction. These include treatments for asthma, psoriasis, infections, high cholesterol, and heart failure, benefiting primary care.

Area of Science:

Pharmaceutical Medicine
Drug Approval Process
Primary Health Care

Background:

The Food and Drug Administration (FDA) plays a crucial role in ensuring drug safety and efficacy.
Primary health care providers require timely updates on new therapeutic options.

Purpose of the Study:

To inform primary health care providers about significant pharmaceutical drug and device approvals in the past year.
To highlight key medications relevant to common patient conditions.

Main Methods:

Review of FDA drug and device approval announcements over the last 12 months.
Identification of drugs with potential impact on primary care practice.

Main Results:

Approval of new medications for urinary incontinence (Oxytrol), genital herpes transmission risk reduction (Valtrex), and hormone therapy (Femring).

More Related Videos

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of ⁶⁸Ga-Labelled Nano Molecules

Published on: October 4, 2024

Related Experiment Videos

Last Updated: Jul 25, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of ⁶⁸Ga-Labelled Nano Molecules

Published on: October 4, 2024

Introduction of treatments for benign prostatic hypertrophy (Uroxatral), erectile dysfunction (Levitra), and influenza prevention (Flumist).

New options for asthma (Xolair), psoriasis (Raptiva), skin infections (Cubicin), hypercholesterolemia (Crestor), and heart failure (Coreg) were also approved.

Conclusions:

The past year saw numerous FDA approvals of drugs addressing a wide spectrum of conditions relevant to primary care.
These new pharmaceutical options offer enhanced treatment strategies for patients across various health domains.